Protara Therapeutics, Inc.
TARA
$3.97
-$0.07-1.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -63.31M | -57.44M | -52.90M | -50.86M | -45.42M |
| Total Depreciation and Amortization | 369.00K | 362.00K | 351.00K | 347.00K | 332.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.18M | 3.65M | 3.54M | 3.47M | 3.98M |
| Change in Net Operating Assets | -4.24M | -2.94M | 285.00K | 2.34M | 966.00K |
| Cash from Operations | -63.00M | -56.37M | -48.72M | -44.71M | -40.14M |
| Capital Expenditure | -50.00K | -94.00K | -70.00K | -74.00K | -107.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -95.81M | -139.40M | -90.01M | -112.89M | -62.19M |
| Cash from Investing | -95.86M | -139.49M | -90.08M | -112.97M | -62.30M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 83.34M | 84.14M | 106.87M | 106.87M | 151.78M |
| Repurchase of Common Stock | -473.00K | -386.00K | -386.00K | -185.00K | -192.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -740.00K | -1.04M | -6.88M | -7.09M | -9.91M |
| Cash from Financing | 82.13M | 82.72M | 99.60M | 99.59M | 141.67M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -76.72M | -113.14M | -39.21M | -58.09M | 39.23M |